Results 11 to 20 of about 11,960 (207)

Early clinical development of artemether-lumefantrine dispersible tablet: palatability of three flavours and bioavailability in healthy subjects [PDF]

Malaria Journal, 2010
Background Efforts to ease administration and enhance acceptability of the oral anti-malarial artemether-lumefantrine (A-L) crushed tablet to infants and children triggered the development of a novel dispersible tablet of A-L. During early development of
Abdulla Salim, Amuri Baraka, Kabanywanyi Abdunoor M, Ubben David, Reynolds Christine, Pascoe Steve, Fitoussi Serge, Yeh Ching-Ming, Nuortti Marja, Séchaud Romain, Kaiser Günther, Lefèvre Gilbert   +11 more
doaj   +2 more sources

Prospective evaluation of artemether-lumefantrine for the treatment of non-falciparum and mixed-species malaria in Gabon [PDF]

Malaria Journal, 2012
Background The recommendation of artemisinin combination therapy (ACT) as first-line treatment for uncomplicated falciparum malaria is supported by a plethora of high quality clinical trials.
Mombo-Ngoma Ghyslain, Kleine Christian, Basra Arti, Würbel Heike, Diop Daisy A, Capan Mesküre, Adegnika Ayola A, Kurth Florian, Mordmüller Benjamin, Joanny Fanny, Kremsner Peter G, Ramharter Michael, Bélard Sabine   +12 more
doaj   +2 more sources

Knowledge among drug dispensers and antimalarial drug prescribing practices in public health facilities in Dar es Salaam [PDF]

Drug, Healthcare and Patient Safety, 2013
Appolinary AR Kamuhabwa,1 Richard Silumbe21Unit of Pharmacology and Therapeutics, School of Pharmacy, Muhimbili University of Health and Allied Sciences, 2Pharmacy Council, Dar es Salaam, TanzaniaBackground: Irrational prescribing and dispensing of ...
Kamuhabwa AA, Silumbe R
doaj   +2 more sources

Implementation of artemether-lumefantrine treatment policy for malaria at health facilities in Tanzania [PDF]

Risk Management and Healthcare Policy, 2011
V Mugoyela1, O Minzi21Department of Medicinal Chemistry, 2Unit of Pharmacology and Therapeutics, School of Pharmacy, Muhimbili University of Health and Allied Sciences, Dar Es Salaam, TanzaniaBackground: The purpose of this study was to compare knowledge
Mugoyela V, Minzi 0
doaj   +2 more sources

Population pharmacokinetics of artemether-lumefantrine plus amodiaquine in patients with uncomplicated Plasmodium falciparum malaria. [PDF]

Br J Clin Pharmacol
Aims Resistance to the artemisinins and the artemisinin‐based combination therapy (ACT) partner drugs has developed in Southeast Asia, and artemisinin resistance has also emerged in eastern Africa. Triple ACTs (triple artemisinin‐based combination therapies, TACT), consisting of two partner drugs with different mechanisms of action and similar ...
Ding J, Hoglund RM, van der Pluijm RW, Callery JJ, Peto TJ, Tripura R, Das S, Châu NH, Promnarate C, Mukaka M, Dysoley L, Fanello C, Onyamboko MA, Anvikar AR, Mayxay M, Smithuis F, von Seidlein L, Dhorda M, Amaratunga C, Faiz MA, Nghia HDT, White NJ, Day NPJ, Dondorp AM, Tarning J.   +24 more
europepmc   +2 more sources

Artemether-lumefantrine treatment of uncomplicated Plasmodium falciparum malaria : a systematic review and meta-analysis of day 7 lumefantrine concentrations and therapeutic response using individual patient data [PDF]

, 2015
Achieving adequate antimalarial drug exposure is essential for curing malaria. Day 7 blood or plasma lumefantrine concentrations provide a simple measure of drug exposure that correlates well with artemether-lumefantrine efficacy.
Mårtensson, A, Sibley, CH, Nsanzabana, C, Bassat, Q, Ringwald, P, Faucher, JF, WorldWide Antimalarial Resistance Network Lumefantrine PK/PD Stu,, Ashley, EA, Hodel, EM, Lindegardh, NL, Davis, TME, Schramm, B, Lefèvre, G, Parikh, S, Mayxay, M, Van Vugt, M, Borrmann, S, McGready, R, Hamed, K, Jullien, V, Workman, LJ, Newton, PN, Stepniewska, K, Vugt, MV, Genton, B, Kiechel, JR, Rombo, L, White, Nicholas, Price, Richard, Kofoed, PE, Piola, P, Barnes, KI, Dahal, P, Aweeka, F, Moreira, C, Tarning, J, Nosten, F, Djimde, AA, Ursing, J, Ngasala, BE, Deloron, P, Karunajeewa, HA, Guérin, PJ, Denis, MB, Marsh, K, WorldWide Antimalarial Resistance Network (WWARN) Lumefantrine PK/PD Study Group, Price, RN, Lindegardh, N, White, NJ, Huang, L, McGready, Rose   +50 more
core   +1 more source

Pharmacokinetic and Pharmacodynamic Characteristics of a new Pediatric Formulation of Artemether-Lumefantrine in African Children with Uncomplicated Plasmodium Falciparum Malaria. [PDF]

, 2011
The pharmacokinetic and pharmacodynamic properties of a new pediatric formulation of artemether-lumefantrine, dispersible tablet, were determined within the context of a multicenter, randomized, parallel-group study.
Lyimo, John, Tekete, Mamadou, Abdulla, Salim, Salim Abdulla, Bassat, Quique, Abdoulaye A. Djimdé, Mandomando, Inacio, Gilbert Lefèvre, Lefèvre, Gilbert, null null, Djimdé, Abdoulaye A, Mamadou Tekete, Borrmann, Steffen, John Lyimo, Quique Bassat, Steffen Borrmann, Inacio Mandomando   +16 more
core   +1 more source

Population Pharmacokinetics and Pharmacodynamics of Artemether and Lumefantrine During Combination Treatment in Children with Uncomplicated Falciparum Malaria in Tanzania. [PDF]

, 2010
The combination of artemether (ARM) and lumefantrine is currently the first-line treatment of uncomplicated falciparum malaria in mainland Tanzania. While the exposure to lumefantrine has been associated with the probability of adequate clinical and ...
Färnert, Anna, Zul Premji, Mårtensson, A, Annerberg, A, Mårtensson, Andreas, Annerberg, A., Andreas Mårtensson, Martensson, A., Bjorkman, A., Ngasala, B., Lindegårdh, N, Hietala, Sofia Friberg, Ngasala, B, Ashton, M., Dahlström, S, Gil, P, Friberg Hietala, Sofia,, Björkman, A, Premji, Z., Björkman, Anders, Sofia Friberg Hietala, Premji, Zul, Farnert, A., Dahlström, Sabina, Hietala, SF, Anna Annerberg, Annerberg, Anna, Anders Björkman, Anna Färnert, Pedro Gil, Lindegårdh, Niklas, Ashton, M, Ngasala, Billy, Michael Ashton, Färnert, A, Niklas Lindegårdh, Dahlstrom, S., Gil, P., Billy Ngasala, Lindegardh, N., Ashton, Michael, Gil, J. P., Premji, Z, Gil, Pedro, Hietala, S.F., Ashton, Michael,, Sabina Dahlström   +46 more
core   +1 more source

Exploration of in Vivo Efficacy of Artemether-Lumefantrine Against Uncomplicated Plasmodium Falciparum Malaria in Under Fives in Tabora Region, Tanzania. [PDF]

, 2013
Tanzania adopted artemether-lumefantrine (AL) as first-line drug for uncomplicated malaria in 2006. Recently, there was an anecdotal report on high malaria recurrence rate following AL treatment in in the (urban and peri-urban), western part of Tanzania.
Minzi, O.M.S., Abdunoor M Kabanywanyi, Kabanywanyi, A.M., Mugittu, K., Joseph, Deokary, Premji, Zulfiqarali, Mugittu, Kefas, Deokary Joseph, Omary MS Minzi, Kabanywanyi, Abdunoor M, Kefas Mugittu, Ruth Hulser, Zulfiqarali Premji, Joseph, D., Premji, Zul, Hulser, Ruth, Minzi, Omary Ms, Hulser, R.   +17 more
core   +1 more source

Dispersible formulation of artemether/lumefantrine: specifically developed for infants and young children. [PDF]

, 2009
Infants and children under five years of age are the most vulnerable to malaria with over 1,700 deaths per day from malaria in this group. However, until recently, there were no WHO-endorsed paediatric anti-malarial formulations available.
Abdulla Salim, Sagara, Issaka, Abdulla, Salim, Sagara Issaka, Salim Abdulla, Issaka Sagara   +5 more
core   +2 more sources